On March 12, 2024, Linden Capital Partners announced the completion of its acquisition of Alcresta Therapeutics, Inc., a leader in commercializing novel enzyme-based products designed to address challenges faced by patients living with gastrointestinal disorders and rare diseases, from Athyrium Capital, Bessemer Venture Partners, Frazier Healthcare Partners, and HealthQuest Capital.

In connection with the acquisition, HealthQuest Capital invested in Alcresta and will continue as a minority shareholder and board member. Wilson Sonsini Goodrich & Rosati advised HealthQuest Capital on the transaction.

Alcresta recently announced 510(k) clearance of its next-generation RELiZORB® (iMMOBILIZED LIPASE) cartridge by the Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA). The next-generation RELiZORB device was developed to address the enteral nutrition needs of a wider population of patients living with rare diseases and is expected to launch in Q2 2024.

The Wilson Sonsini team that advised HealthQuest Capital in connection with the transaction included Rob Suffoletta, Myra Sutanto Shen, Anthony Yanez, and Darius Dills.

For more information, please refer to Alcresta Therapeutics’ news release.